0000914190-19-000488.txt : 20191217
0000914190-19-000488.hdr.sgml : 20191217
20191217163244
ACCESSION NUMBER: 0000914190-19-000488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191212
FILED AS OF DATE: 20191217
DATE AS OF CHANGE: 20191217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Furlow Brenda S.
CENTRAL INDEX KEY: 0001443851
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 191290116
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-12-12
0000842023
BIO-TECHNE Corp
TECH
0001443851
Furlow Brenda S.
614 MCKINLEY PLACE NE
MINNEAPOLIS
MN
55413
0
1
0
0
SVP - General Counsel
Common Stock
2019-11-12
5
G
0
492
0
D
2711
D
Common Stock
2019-12-12
4
M
0
8000
94.35
A
10711
D
Common Stock
2019-12-12
4
S
0
426
214.3196
D
10285
D
Common Stock
2019-12-12
4
S
0
3227
215.1651
D
7058
D
Common Stock
2019-12-12
4
S
0
4147
216.0077
D
2911
D
Common Stock
2019-12-12
4
S
0
200
216.75
D
2711
D
Stock Options (Right to Buy)
94.35
2019-12-12
4
M
0
8000
0
D
2021-08-12
Common Stock
8000
1600
D
Stock Options (Right to Buy)
108.49
2022-08-07
Common Stock
10000
10000
D
Stock Options (Right to Buy)
108.49
2022-08-07
Common Stock
5995
5995
D
Stock Options (Right to Buy)
106.59
2023-08-18
Common Stock
10857
10857
D
Stock Options (Right to Buy)
106.59
2023-08-18
Common Stock
14476
14476
D
Restricted Stock Units
Common Stock
1724
1724
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
9503
9503
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
12670
12670
D
Restricted Stock Units
Common Stock
1374
1374
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
7339
7339
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
9786
9786
D
Restricted Stock Units
Common Stock
1969
1969
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
9968
9968
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
13290
13290
D
Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.67 to $214.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.69 to $215.68 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.69 to $216.53 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.71 to $216.79 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Fully exercisable.
Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed.
2019-12-17